Latest Multiple Myeloma Research Foundation Stories
QUEBEC CITY, March 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
Trial conducted pursuant to Special Protocol Assessment with the Food and Drug Administration QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
NEW YORK, Dec. 16 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
NEW ORLEANS, Dec. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
NEW YORK, Dec.
Co-Pay Relief Program Provides Direct Financial Support for Pharmaceutical Co-Payments to Insured Patients in Medical and Financial Need WASHINGTON, Nov.
Multiple myeloma cancer cells thwart many of the drugs used against them by causing nearby cells to turn traitor â€“ to switch from defending the body against disease to shielding the myeloma cells from harm â€“ Dana-Farber Cancer Institute scientists report in the October issue of Cancer Cell.
HACKENSACK, N.J., Sept. 30 /PRNewswire/ -- The John Theurer Cancer Center at Hackensack University Medical Center today proudly announced the addition of David H. Vesole, M.D., Ph.D., F.A.C.P. to its Multiple Myeloma Division. He will join division chief David S.
The International Myeloma Foundation (IMF)â€”supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians
Scientists at the Institute for Myeloma and Bone Cancer Research (IMBCR) have uncovered a new pathway that could explain how blood vessels form within tumors. LOS ANGELES, Feb.
- A poem in which the author retracts something said in an earlier poem.